Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | ALB | P02768 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | TK1 | P04183 | 7/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13286394 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL27505365 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL23485 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL14596607 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL925743 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL29711774 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL14421795 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL762579 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL22992337 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| Methane SCHEMBL25262791 | 0.99 | TK1 (0.57) | LMNAALBBLMALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5187266-A | Cytotoxic, viricidal | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-02-16 | — | — | US | claimed |
| EP-0483130-A1 | NOVEL ANTITUMOR ALDOPHOSPHAMIDE ANALOGS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-05-06 | — | — | EP | claimed |
| US-4968788-A | DRUG DELIVERY, ANTITUMOR AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1990-11-06 | — | — | US | claimed |
| WO-1990010636-A1 | NOVEL ANTITUMOR ALDOPHOSPHAMIDE ANALOGS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1990-09-20 | — | — | WO | claimed |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-02 | — | — | US | disclosed |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | UNIV CALIFORNIA (US) | 2021-10-28 | — | — | US | disclosed |
| US-5631239-A | VIRICIDES FOR HEPATITIS | YALE UNIVERSITY (US) | 1997-05-20 | — | — | US | disclosed |
| US-5187266-A | Cytotoxic, viricidal | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-02-16 | — | — | US | disclosed |
| EP-0483130-A1 | NOVEL ANTITUMOR ALDOPHOSPHAMIDE ANALOGS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-05-06 | — | — | EP | disclosed |
| US-5091552-A | Novel antitumor aldophosphamide analogs | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-02-25 | — | — | US | disclosed |
| WO-1990010636-A1 | NOVEL ANTITUMOR ALDOPHOSPHAMIDE ANALOGS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1990-09-20 | — | — | WO | disclosed |
| WO-1990008155-A1 | BIOLOGICALLY REVERSIBLE PHOSPHATE AND PHOSPHONATE PROTECTIVE GROUPS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1990-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885ALB 2637/4885BLM 1025/4885 |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885ALB 2637/4885BLM 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.